268 related articles for article (PubMed ID: 10022535)
1. Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev.
Ragheb JA; Couture L; Mullen C; Ridgway A; Morgan RA
Hum Gene Ther; 1999 Jan; 10(1):103-12. PubMed ID: 10022535
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human immunodeficiency virus-1 production resulting from transduction with a retrovirus containing an HIV-regulated diphtheria toxin A chain gene.
Harrison GS; Long CJ; Curiel TJ; Maxwell F; Maxwell IH
Hum Gene Ther; 1992 Oct; 3(5):461-9. PubMed ID: 1329991
[TBL] [Abstract][Full Text] [Related]
3. Activation of a diphtheria toxin A gene by expression of human immunodeficiency virus-1 Tat and Rev proteins in transfected cells.
Harrison GS; Maxwell F; Long CJ; Rosen CA; Glode LM; Maxwell IH
Hum Gene Ther; 1991; 2(1):53-60. PubMed ID: 1863640
[TBL] [Abstract][Full Text] [Related]
4. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
Peng H; Callison D; Li P; Burrell C
Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
Mautino MR; Keiser N; Morgan RA
J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes.
Bauer G; Valdez P; Kearns K; Bahner I; Wen SF; Zaia JA; Kohn DB
Blood; 1997 Apr; 89(7):2259-67. PubMed ID: 9116267
[TBL] [Abstract][Full Text] [Related]
7. Long-term inhibition of clinical and laboratory human immunodeficiency virus strains in human T-cell lines containing an HIV-regulated diphtheria toxin A chain gene.
Curiel TJ; Cook DR; Wang Y; Hahn BH; Ghosh SK; Harrison GS
Hum Gene Ther; 1993 Dec; 4(6):741-7. PubMed ID: 8186289
[TBL] [Abstract][Full Text] [Related]
8. Protection of primary human T cells from HIV infection by Trev: a transdominant fusion gene.
Chinen J; Aguilar-Cordova E; Ng-Tang D; Lewis DE; Belmont JW
Hum Gene Ther; 1997 May; 8(7):861-8. PubMed ID: 9143912
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.
Braun SE; Wong FE; Connole M; Qiu G; Lee L; Gillis J; Lu X; Humeau L; Slepushkin V; Binder GK; Dropulic B; Johnson RP
Mol Ther; 2005 Dec; 12(6):1157-67. PubMed ID: 16168713
[TBL] [Abstract][Full Text] [Related]
10. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein.
Schwartz S; Felber BK; Pavlakis GN
J Virol; 1992 Jan; 66(1):150-9. PubMed ID: 1727477
[TBL] [Abstract][Full Text] [Related]
11. A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy, and sense RNAs, and trans-dominant negative mutant Gag and Env proteins.
Ding SF; Lombardi R; Nazari R; Joshi S
Front Biosci; 2002 Feb; 7():a15-28. PubMed ID: 11815282
[TBL] [Abstract][Full Text] [Related]
12. The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance.
Liem SE; Ramezani A; Li X; Joshi S
Hum Gene Ther; 1993 Oct; 4(5):625-34. PubMed ID: 8280800
[TBL] [Abstract][Full Text] [Related]
13. Transient protection of human T-cells from human immunodeficiency virus type 1 infection by transduction with adeno-associated viral vectors which express RNA decoys.
Smith C; Lee SW; Wong E; Gallardo H; Page K; Gaspar O; Lebkowski J; Gilboa E
Antiviral Res; 1996 Oct; 32(2):99-115. PubMed ID: 8891169
[TBL] [Abstract][Full Text] [Related]
14. High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector.
Fraisier C; Irvine A; Wrighton C; Craig R; Dzierzak E
Gene Ther; 1998 Dec; 5(12):1665-76. PubMed ID: 10023446
[TBL] [Abstract][Full Text] [Related]
15. Analysis of trans-dominant mutants of the HIV type 1 Rev protein for their ability to inhibit Rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics.
Ragheb JA; Bressler P; Daucher M; Chiang L; Chuah MK; VandenDriessche T; Morgan RA
AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1343-53. PubMed ID: 8573391
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
Mautino MR; Morgan RA
Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
[TBL] [Abstract][Full Text] [Related]
17. Down-modulation of TCR/CD3 surface complexes after HIV-1 infection is associated with differential expression of the viral regulatory genes.
Willard-Gallo KE; Furtado M; Burny A; Wolinsky SM
Eur J Immunol; 2001 Apr; 31(4):969-79. PubMed ID: 11298321
[TBL] [Abstract][Full Text] [Related]
18. Helper plasmids for production of HIV-1-derived vectors.
Fuller M; Anson DS
Hum Gene Ther; 2001 Nov; 12(17):2081-93. PubMed ID: 11747598
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of HIV-1 by a double transdominant fusion gene.
Aguilar-Cordova E; Chinen J; Donehower LA; Harper JW; Rice AP; Butel JS; Belmont JW
Gene Ther; 1995 May; 2(3):181-6. PubMed ID: 7614248
[TBL] [Abstract][Full Text] [Related]
20. Retroviral vector with a CMV-IE/HIV-TAR hybrid LTR gives high basal expression levels and is up-regulated by HIV-1 Tat.
Robinson D; Elliott JF; Chang LJ
Gene Ther; 1995 Jun; 2(4):269-78. PubMed ID: 7552987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
